---
schema_version: "secwatch.filing_event.v1"
accession: "0001558370-23-002685"
form_type: "8-K"
ticker: "XLO"
cik: "0001840233"
company_name: "Xilio Therapeutics, Inc."
filed_at: "2023-03-02T23:59:59+00:00"
generated_at: "2026-06-18T16:06:19.403072+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# Xilio reports FY2022 net loss $88.2M; cash $120.4M; XTX202 shows early tumor-selective activation

## Summary
- Cash and cash equivalents $120.4M as of Dec 31, 2022, down from $198.1M; cash runway into Q2 2024.
- Net loss for FY2022 was $88.2M vs $75.8M in 2021; Q4 net loss $22.5M vs $19.7M.
- XTX202 (tumor-activated IL-2) showed preliminary pharmacodynamic evidence of tumor-selective activation in two patients; no vascular leak syndrome observed.
- XTX202 Phase 2 monotherapy trial in melanoma and RCC to initiate April 2023; preliminary Phase 1/2 data expected Q3 2023.
- XTX101 (anti-CTLA-4) RP2D set at 150 mg Q6W; preliminary Phase 1 data expected Q2 2023; exploring partnership.

## SEC filing metadata
- accession: 0001558370-23-002685
- form_type: 8-K
- ticker: XLO
- cik: 0001840233
- company_name: Xilio Therapeutics, Inc.
- filed_at: 2023-03-02T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1840233/000155837023002685/0001558370-23-002685-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1840233/000155837023002685/xlo-20230302x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001558370-23-002685
- JSON: https://secwatch.observer/filing/0001558370-23-002685.json
- Plain text: https://secwatch.observer/filing/0001558370-23-002685.txt

## Key facts
- Earnings Releases
  Xilio Therapeutics, Inc. reported financial results for the fourth quarter and full year ended December 31, 2022.
  - Period: the fourth quarter and full year ended December 31, 2022
  - Result: reported results
  source text: On March 2, 2023, Xilio Therapeutics, Inc. (the “Company”) announced its financial results for the quarter and year ended December 31, 2022 and other business highlights.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1840233/000155837023002685/0001558370-23-002685-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.